PGEN Insider Purchase: Director Nancy Agee Adds 15,000 Shares
Rhea-AI Filing Summary
Nancy H. Agee, a director of Precigen, Inc. (PGEN), reported purchasing 15,000 shares of the company's common stock on 09/04/2025 at a price of $4.60 per share. After the purchase she beneficially owns 217,841 shares, held directly. The filing shows no derivative transactions and was signed on 09/05/2025 by Nancy H. Agee via attorney-in-fact.
Positive
- Director purchase disclosed: Nancy H. Agee acquired 15,000 common shares, indicating insider buying activity.
- Increased direct ownership: Beneficial ownership rose to 217,841 shares following the transaction.
- Clean disclosure: No derivatives reported and the Form 4 was timely signed, meeting Section 16 reporting requirements.
Negative
- None.
Insights
TL;DR: A director executed an open-market purchase of common stock, modestly increasing direct ownership.
The Form 4 documents a straightforward non-derivative purchase: 15,000 shares at $4.60 each, raising direct beneficial ownership to 217,841 shares. This is a routine insider buy disclosed under Section 16 and does not include options, warrants, or other derivative instruments. The size of the purchase relative to total outstanding shares is not provided in the filing, so materiality to valuation cannot be determined from this document alone.
TL;DR: Insider purchase by a director is a governance signal but lacks context on size and intent.
The filing confirms the transaction was reported promptly and executed directly, which aligns with disclosure obligations. There is no indication of Rule 10b5-1 plan or other arrangements disclosed on the form. Without information on the director's historical trading pattern or the company's share count, implications for control or voting power cannot be assessed from this filing alone.